Biogen Inc. (BIIB) is a global biotechnology company that develops and commercializes therapies for serious and complex diseases. Headquartered in Cambridge, Massachusetts, Biogen has built a strong presence in neurology, specialized immunology, and rare diseases, with a portfolio spanning multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, ALS, and other conditions.
Companies worth $10 billion or more are typically classified as "large-cap stocks," and Biogen, with a market cap of $32.1 billion, fits the label perfectly. Biogen's core strength lies in its deep neuroscience expertise and a portfolio of established therapies for complex neurological and rare diseases. Its long-standing research capabilities, specialized commercial infrastructure, and broad pipeline also provide scale and expertise that smaller biotech rivals can find hard to replicate.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Nvidia CEO Jensen Huang Just Dropped Huge News for This Cybersecurity Stock
How to Play GME Stock as GameStop CEO Ryan Cohen Buys $20.3 Million in Shares

#biogen #complex #expertise

Wolfe Research upgraded two prominent pharmaceutical companies to Outperform on August 13. The firm upgraded both Biogen Inc. (NASDAQ:BIIB) and AbbVie Inc. (NYSE:ABBV)'s ratings from Peer Perform, with Wolfe ***** igning them similar $300 price targets. The firm's logic in each case was based on a comparable set of factors: pipelines that the market appears to undervalue, and valuations that Wolfe believes are too low given each company's growth track.
Wolfe's thesis for Biogen Inc. (NASDAQ:BIIB) is mainly based on late-stage clinical programs, which it believes the stock has yet to reflect. The firm focused on two experimental therapies in particular, both of which have key late-stage clinical readouts expected over the coming year: litifilimab, which Wolfe believes could be the first biologic approved for cutaneous lupus erythematosus, and felzartamab, which the firm claims represents a bigger commercial opportunity in antibody-mediated transplant rejection than Wall Street currently thinks.
Wolfe also cited Biogen's acquisition of Apellis Pharmaceuticals as strengthening its near-term revenue base through the FDA-approved drugs Empaveli and Syfovre. That move is part of an overall pattern of Biogen Inc. (NASDAQ:BIIB) diversifying beyond its core neurology brand, with the company completing its acquisition of RayThera on August 6, adding another early-stage immunology platform to its pipeline.
Wolfe's Biogen Inc. (NASDAQ:BIIB) thesis is incomplete without valuation. The firm believes the stock is trading at a discount to the broader market, despite the company's development on Leqembi, its Alzheimer's medication, and what Wolfe described as solid commercial execution overall.
AbbVie's upgrade is based on a slightly different premise: patent strength and cash generation rather than simple clinical events. Wolfe stated that AbbVie's 2027 earnings multiple of 14.6x seemed too low for a company that forecasts high-single-digit revenue growth for the rest of the decade. AbbVie's patent position, according to Wolfe, sets the company apart from its competitors in a way that the market has yet to completely price in.

#wolfe #firm #market #clinical

In a recent interview on CNBC's Halftime Report, Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (NASDAQ: INCY) and Biogen (NASDAQ: BIIB) as two of his "Best Stocks in the Market." Brown said he wanted to focus on stocks that had "nothing to do" with the AI and data-center spending theme.
"We wanted to do something that had nothing to do with data centers and GPUs and just take a break from that whole AI capex world that we've been living in for so long," Brown said. "We wanted to talk about stocks that are working away from that."
Brown likes Biogen because of strong fundamentals and the company's strong earnings performance.
But in this article, we will focus on Incyte, which is up 22% so far this year.
Brown's bullish case for Incyte centers on its strong earnings momentum and expanding drug pipeline. Brown said the company has a pipeline of roughly nine or 10 drugs at various stages of development, creating multiple potential catalysts for future growth.

#focus #data

Updated July 29, 2026, 12:21 pm EDT / Original July 29, 2026, 6:02 am EDT
As revenue continues to fall within Biogen’s
BIIB
-0.62%
market-leading
multiple sclerosis franchise
, the company is leaning on a handful of other drugs to drive growth. The strategy appears to be working.
BIIB
-0.62%
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

#company #jones #rights

July 29 (Reuters) - Biogen reported second-quarter profit and revenue that topped Wall Street estimates on Wednesday, driven by strong demand ‌for its rare-disease medicines, while sales of its legacy multiple ‌sclerosis drugs stayed under pressure.
Investors are closely watching whether recent deals and newer products including its Alzheimer's drug Leqembi can reignite growth and help the company navigate mounting competition and pricing pressure across its aging multiple sclerosis portfolio.
Despite an upbeat quarter, Biogen cut its 2026 adjusted per-share profit forecast to ‌between $12 and $13 from between $14.25 ⁠and $15.25 per share earlier, reflecting a $3.85 per share impact from acquisition-related charges.
Analysts were expecting 2026 profit of $12.72 per ⁠share, according to data compiled by LSEG.
The drugmaker said its $5.6 billion buyout of Apellis Pharmaceuticals earlier this year would account for an 85-cent-per-share hit to annual profit.

#biogen #quarter #july

At midday, the Nasdaq Composite (NASDAQINDEX:^IXIC) slipped 1.06% to 26,002.95, and the S&P 500 (SNPINDEX:^GSPC) fell 0.49% to 7,538.37 as growth sectors faltered, while the Dow Jones Industrial Average (DJINDICES:^DJI) declined 0.26% to 52,501.95.
Gold prices dropped 1.78% to $4,015.70 as of midday, and the 10-Year Treasury yield rose 0.03% to 4.60%. Consumer defensive stocks gained 1.03% while healthcare stocks dropped 1.08%.
Memory stocks dipped this morning after SK Hynix stocks plunged in South Korea. Last week, the chipmaker soared after its debut on U.S. exchanges, but today, investors sold off following a brokerage report suggesting it may not meet its quarterly profit estimates. The jitters dragged on peers, including Micron Technology, Seagate Technology, and Sandisk. Biogen gained following a Truist upgrade citing optimism for the company's Alzheimer's pipeline.
The prospect of further disruptions to oil supplies and increased hostilities in the Middle East weighed on stocks this morning. WTI crude surged 4.6% to almost $75 a barrel amid reports of renewed clashes between the U.S. and Iran, and potential restrictions on transit through the Strait of Hormuz.
Airline stocks, which had begun to recover on hopes of a full peace deal, dropped, and investors shifted again to defensive stocks. The worry is that elevated energy prices could fuel higher inflation, which could cause the Federal Reserve to raise interest rates and reduce risk appetite. All eyes will be on major banks this week as they kick off the second-quarter earnings season for clues about the resilience of consumers' financials and the economy.

Biogen (NASDAQ: BIIB) built itself into a biotech giant thanks to its portfolio of multiple sclerosis (MS) drugs -- but in biotech and pharma, revenue growth depends on the life of a patent. Once a company loses exclusivity, generics or biosimilars enter the market, and the leader's drug sales decline. This is the challenge Biogen has faced in recent years, as MS blockbusters faced growing competition.
But the biotech giant put into place a recovery and growth plan, shifting many costs out of the MS franchise and into areas that represented growth potential. Biogen also made strategic acquisitions, announcing its intention to buy Apellis Pharmaceuticals, an immunology and rare diseases drug company, in March and closing the deal in May.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
And just recently, Biogen announced another purchase. This time, the biotech is paying $1 billion for a company that won't say what it makes. Here's why this actually is good news for Biogen investors.
Let's start with a quick update on Biogen. As mentioned, the biotech company was once known as an MS giant, and it still sells a number of important MS drugs, such as Tecfidera and Tysabri. But loss of exclusivity made a significant dent in revenue, with Tecfidera's peak sales of $4.4 billion in 2019 dropping to $1.4 billion in 2022. In the latest fiscal year, all of Biogen's MS drugs, together, delivered $4 billion in revenue, further highlighting this decline.